S-777469, a novel cannabinoid type 2 receptor agonist, suppresses itch-associated scratching behavior in rodents through inhibition of itch signal transmission

Pharmacology

Volumn 95, Issue , 2015, Pages 95-103

  Haruna, Takayo ^a   Soga, Masahiko ^b   Morioka, Yasuhide ^b   Hikita, Ichiro ^c   Imura, Kinichi ^d   Furue, Yoko ^e   Yamamoto, Mina ^a   Imura, Chihiro ^a   Ikeda, Minoru ^b   Yamauchi, Akira ^b   Deguchi, Masashi ^c   Shichijo, Michitaka ^a   Arimura, Akinori ^d   Yasui, Kiyoshi ^e  

^a Discovery Research Laboratory for Innovative Frontier Medicines   (Japan)

^b Discovery Research Laboratory for Core Therapeutic Areas   (Japan)

^c Pharmaceutical Research Division   (Japan)

^d Global Project Management   (Japan)

^e SHIONOGI AND CO LTD   (Japan)

Author keywords

Antipruritic agent; Cannabinoid type 2 receptor; Itch; S 777469

Indexed keywords

1 [[6 ETHYL 1 (4 FLUOROBENZYL) 5 METHYL 2 OXO 1,2 DIHYDROPYRIDINE 3 CARBONYL]AMINO]CYCLOHEXANECARBOXYLIC ACID; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIPRURITIC AGENT; CANNABINOID 2 RECEPTOR AGONIST; COMPOUND 48-80; FEXOFENADINE; HISTAMINE; SEROTONIN; SUBSTANCE P; UNCLASSIFIED DRUG; 4 METHOXY N METHYLPHENETHYLAMINE; CANNABINOID 2 RECEPTOR; PYRIDONE DERIVATIVE; S-777469;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPERIMENTAL PRURITUS; FEMALE; JAPANESE WHITE (RABBIT); MOUSE; NONHUMAN; PERIPHERAL NERVE; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SCRATCHING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TABLET; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; FISCHER 344 RAT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PRURITUS; SPINAL GANGLION;

ANIMALS; BEHAVIOR, ANIMAL; FEMALE; GANGLIA, SPINAL; HISTAMINE; MICE, INBRED ICR; NEURONS; P-METHOXY-N-METHYLPHENETHYLAMINE; PRURITUS; PYRIDONES; RATS, INBRED F344; RECEPTOR, CANNABINOID, CB2; SEROTONIN; SIGNAL TRANSDUCTION; SUBSTANCE P;

EID: 84924166376     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000371890     Document Type: Article

References (38)

1. Rothman S: Physiology of itching. Physiol Rev 1941; 21: 357-381.
2. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, et al: Itch: scratching more than the surface. QJM 2003; 96: 7-26.
3. Handwerker HO, Forster C, Kirchhoff C: Discharge patterns of human C-fibers induced by itching and burning stimuli. J Neurophysiol 1991; 66: 307-315.
4. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE: Specific C-receptors for itch in human skin. J Neurosci 1997; 17: 8003-8008.
5. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjörk HE, Handwerker HO: Chemical response pattern of different classes of Cnociceptors to pruritogens and algogens. J Neurophysiol 2003; 89: 2441-2448.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
7. Herkenham M, Lynn AB, Little MD, Ross Johnson M, Melvin LS, De Costa BR, et al: Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
8. Pertwee RG: Evidence for the presence of CB 1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB 1 cannabinoid receptors. Life Sci 1999; 65: 597-605.
9. Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I: Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cellderived neurotrophic factor-responsive primary sensory neurones. Neuroscience 2002; 110: 747-753.
10. Klein TW, Newton CA, Friedman H: Cannabinoids and the immune system. Pain Res Manag 2001; 6: 95-101.
11. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al: HU-308: a specific agonist for CB 2 , a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96: 14228-14233.
12. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al: Activation of CB 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100: 10529-10533.
13. Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, et al: New 1,8-naphthyridine and quinoline derivatives as CB 2 selective agonists. Bioorg Med Chem Lett 2007; 17: 6505-6510.
14. Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papahatjis DP, Makriyannis A: Cannabilactones: a novel class of CB 2 selective agonists with peripheral analgesic activity. J Med Chem 2007; 50: 6493-6500.
15. Omura H, Kawai M, Shima A, Iwata Y, Ito F, Masuda T, et al: The SAR studies of novel CB 2 selective agonists, benzimidazolone derivatives. Bioorg Med Chem Lett 2008; 18: 3310-3314.
16. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al: Characterization of a cannabinoid CB 2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 2009; 328: 141-151.
17. Dvorak M, Watkinson A, McGlone F, Rukwied R: Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003; 52: 238-245.
18. Ständer S, Reinhardt HW, Luger TA: Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt 2006; 57: 801-807.
19. Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, et al: Discovery of S-777469: an orally available CB 2 agonist as an antipruritic agent. Bioorg Med Chem Lett 2012; 22: 2803-2806.
20. Nojima H, Carstens E: 5-Hydroxytryptamine (5-HT) 2 receptor involvement in acute 5-HTevoked scratching but not in allergic pruritus induced by dinitrofluorobenzene in rats. J Pharmacol Exp Ther 2003; 306: 245-252.
21. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M: The neurobiology of itch. Nat Rev Neurosci 2006; 7: 535-547.
22. Ständer S, Weisshaar E, Luger TA: Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008; 7: 161-169.
23. Liu T, Ji RR: New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms? Pflugers Arch 2013; 465: 671-685.
24. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995; 275: 229-233.
25. Anand U, Otto WR, Sanchez-Herrera D, Facer P, Yiangou Y, Korchev Y, et al: Cannabinoid receptor CB 2 localisation and agonistmediated inhibition of capsaicin responses in human sensory neurons. Pain 2008; 138: 667-680.
26. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V: Inhibitory effects of CB 1 and CB 2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 2005; 22: 371-379.
27. Ständer S, Schmelz M, Metze D, Luger T, Rukwied R: Distribution of cannabinoid receptor 1 (CB 1 ) and 2 (CB 2 ) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38: 177-188.
28. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG: Activation of cannabinoid CB 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 2004; 92: 3562-3574.
29. Maekawa T, Nojima H, Kuraishi Y: Itch-associated responses of afferent nerve innervating the murine skin: different effects of histamine and serotonin in ICR and ddY mice. Jpn J Pharmacol 2000; 84: 462-466.
30. Andoh T, Katsube N, Maruyama M, Kuraishi Y: Involvement of leukotriene B 4 in substance P-induced itch-associated response in mice. J Invest Dermatol 2001; 117: 1621-1626.
31. Kajihara Y, Murakami M, Imagawa T, Otsuguro K, Ito S, Ohta T: Histamine potentiates acid-induced responses mediating transient receptor potential V1 in mouse primary sensory neurons. Neuroscience 2010; 166: 292-304.
32. Nicholson R, Small J, Dixon AK, Spanswick D, Lee K: Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. Neurosci Lett 2003; 337: 119-122.
33. Andoh T, Nagasawa T, Kuraishi Y: Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. Brain Res Mol Brain Res 1996; 35: 329-332.
34. Andoh T, Kuraishi Y: Expression of BLT1 leukotriene B 4 receptor on the dorsal root ganglion neurons in mice. Brain Res Mol Brain Res 2005; 137: 263-266.
35. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al: CB 2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006; 23: 1530-1538.
36. Bouaboula M, Dussossoy D, Casellas P: Regulation of peripheral cannabinoid receptor CB 2 phosphorylation by the inverse agonist SR 144528. J Biol Chem 1999; 274: 20397-20405.
37. Grimsey NL, Goodfellow CE, Dragunow M, Glass M: Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta 2011; 1813: 1554-1560.
38. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K: Functional selectivity in CB 2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB 2 ligands. Mol Pharmacol 2012; 81: 250-263.